Shilpa Medicare
Ticker > Company >

Shilpa Medicare share price

Shilpa Medicare Ltd.

NSE: SHILPAMED BSE: 530549 SECTOR: Pharmaceuticals & Drugs  78.56 K   186   35

826.30
+1.55 (0.19%)
NSE: 16 Sep 04:07 PM

Price Summary

Today's High

₹ 837.8

Today's Low

₹ 812.7

52 Week High

₹ 1000

52 Week Low

₹ 555

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 8080.46 Cr.

Enterprise Value

₹ 8219.88 Cr.

No. of Shares

9.78 Cr.

P/E

130.01

P/B

2.97

Face Value

₹ 1

Div. Yield

0.12 %

Book Value (TTM)

₹  278.28

CASH

₹ 3.13 Cr.

DEBT

₹ 142.55 Cr.

Promoter Holding

44.23 %

EPS (TTM)

₹  6.36

Sales Growth

25.06%

ROE

1.26 %

ROCE

2.36%

Profit Growth

154.44 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.06%
3 Year6.42%
5 Year-14.14%

Profit Growth

1 Year-52.9%
3 Year-47.33%
5 Year-26.33%

ROE%

1 Year1.26%
3 Year0%
5 Year3.3%

ROCE %

1 Year2.36%
3 Year0.79%
5 Year4.03%

Debt/Equity

0.0665

Price to Cash Flow

1005.82

Interest Cover Ratio

3.2072

CFO/PAT (5 Yr. Avg.)

1.66048637379028

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 44.23 7.92
Mar 2025 44.23 7.92
Dec 2024 44.23 7.92
Sep 2024 44.33 7.90
Jun 2024 44.39 90.41
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 144.8696 Cr.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.841811876422894.
  • The company has an efficient Cash Conversion Cycle of 77.7921 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.66048637379028.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 4.96846968619313.

 Limitations

  • The company has shown a poor profit growth of -25.4800278584316% for the Past 3 years.
  • The company has shown a poor revenue growth of 6.41784374112666% for the Past 3 years.
  • Company has a poor ROE of -0.00419547935880008% over the past 3 years.
  • Company has a poor ROCE of 0.786698899258323% over the past 3 years
  • Company has contingent liabilities of 655.2432 Cr.
  • The company is trading at a high PE of 130.01.
  • The company is trading at a high EV/EBITDA of 43.6324.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 96.12 129.68 125.39 126.15 92.43
Total Expenditure 72.76 86.83 102.82 90.92 75.43
Operating Profit 23.36 42.86 22.56 35.23 17
Other Income 31.4 21.47 16.83 14.08 17.79
Interest 1.77 1.19 1.38 2.09 2.23
Depreciation 12.3 12.02 12.2 12.34 12.59
Exceptional Items -0.46 -0.47 -0.49 -44.32 -5.18
Profit Before Tax 40.23 50.65 25.33 -9.43 14.78
Tax 12.34 20.16 9.21 -4.28 -5.91
Profit After Tax 27.88 30.49 16.12 -5.15 20.7
Adjusted EPS (Rs) 2.85 3.12 1.65 -0.53 2.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 805.97 257.05 356.95 247.7 309.79
Total Expenditure 568.18 228.58 345.93 302.88 287.72
Operating Profit 237.79 28.47 11.02 -55.17 22.07
Other Income 18.37 37.14 51.52 79.82 93.34
Interest 4.33 6.07 9.05 20.83 17.26
Depreciation 34.96 22.28 34.82 46.55 49.61
Exceptional Items -4.54 52.95 8.81 -15.55 -10.45
Profit Before Tax 212.34 90.21 27.49 -58.28 38.09
Tax 44.15 25.12 7.33 -8.79 11.15
Net Profit 193.72 184.39 140.99 57.19 26.94
Adjusted EPS (Rs.) 20.63 7.98 2.32 -5.7 3.1

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 8.15 8.15 8.68 8.68 8.68
Total Reserves 1445.27 1629.68 2056.99 2108.9 2134.04
Borrowings 164.48 324.52 120.28 122.8 16.25
Other N/C liabilities 43.52 81.06 89.87 35.56 33.28
Current liabilities 359.86 473.98 161.65 242.71 226.34
Total Liabilities 2021.28 2517.39 2896.12 2518.66 2418.58
Assets
Net Block 517 640.9 565.78 608.93 586.33
Capital WIP 244.18 297.19 52.57 41.84 9.92
Intangible WIP 128.63 185.16 240.55 184.59 218.32
Investments 93.48 219.32 237.5 243.92 246.45
Loans & Advances 124.54 391.84 595.14 802.92 980.26
Other N/C Assets 5.76 3.1 895.15 0.2 0.38
Current Assets 907.69 779.9 309.44 636.25 376.93
Total Assets 2021.28 2517.39 2896.12 2518.66 2418.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 233.99 255.54 192.89 12.68 38.09
Adjustment -5.39 -25.46 32.64 -35.56 7.17
Changes in Assets & Liabilities -57.95 -117.1 -17.17 33.37 -30.28
Tax Paid -40.85 -43.34 -34.49 -8.41 -6.95
Operating Cash Flow 129.79 69.63 173.87 2.08 8.03
Investing Cash Flow -302.49 -238.13 -378.97 -94.83 155.82
Financing Cash Flow 170.1 255.58 97.23 87.68 -163.07
Net Cash Flow -2.59 87.08 -107.88 -5.07 0.78

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 44.39 44.33 44.23 44.23 44.23
brijgopal innani 1.20 1.20 1.20 1.20 1.20
deepak kumar innani 2.80 2.80 2.80 2.80 2.80
dharmavati bhutada 6.35 6.35 6.35 6.35 6.35
kamalkishore innani 0.17 0.17 0.17 0.17 0.17
kantadevi inani 2.60 2.60 2.60 2.60 2.60
keerti innani 0.16 0.16 0.16 0.16 0.16
keshav bhutada 2.05 2.05 2.05 2.05 2.05
madhav vishnukant bhutada... 2.05 2.05 2.05 2.05 2.05
manjulatha innani 0.16 0.16 0.16 0.16 0.16
namrata bhutada 0.02 0.02 0.02 0.02 0.02
natamal innani 1.16 1.16 1.16 1.16 1.16
om prakash inani 2.93 2.93 2.93 2.93 2.93
priya inani - 0.18 0.08 0.08 0.08
ramakant innani 1.53 1.53 1.53 1.53 1.53
ravi kumar innani 4.10 4.10 4.10 4.10 4.10
sagar innani 1.02 1.02 1.02 1.02 1.02
shakuntalabai innani 1.15 1.15 1.15 1.15 1.15
suraj kumar inani - 4.01 4.01 4.01 4.01
taradevi innani 1.28 1.28 1.28 1.28 1.28
triveni inani 0.30 0.30 0.30 0.30 0.30
vishnukant chaturbhuj bhu... 6.51 6.51 6.51 6.51 6.51
vishnukanta inani 1.24 1.24 1.24 1.24 1.24
vishnukanth c bhutada (hu... 1.37 1.37 1.37 1.37 1.37
priya innani 0.18 - - - -
suraj kumar innani 4.07 - - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 55.61 55.67 55.77 55.77 55.77
akash bhanshali 1.64 1.55 1.55 1.52 1.52
amal parikh - - - - 1.73
bandhan nifty total marke... - - - - 1.33
cohesion mk best ideas su... 2.12 2.12 2.17 2.17 2.17
dovetail india fund class... 1.52 1.52 1.52 1.52 1.52
elm park fund limited 1.23 1.23 1.23 1.23 1.23
icici prudential pharma h... 2.82 2.74 - - 2.04
investor education and pr... - - 0.29 - 0.29
pivotal enterprises priva... 2.25 2.25 2.25 2.25 2.25
sapphire intrex limited 1.09 1.09 1.09 1.09 1.09
sbi life insurance co. lt... 1.25 1.61 1.72 1.75 1.73
bandhan small cap fund 1.59 - 1.92 1.45 -
icici prudential elss tax... - - 2.40 2.04 -
investor education and pr... 0.29 0.29 - 0.29 -
viral parikh - - 1.02 1.02 -
bandhan core equity fund - 1.74 - - -
viral amal parikh 1.02 1.02 - - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2025
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
Credit ICRA
Credit CRISIL
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
Research BP Wealth

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY23
Concall Q3FY24
Concall Q3FY24
Concall Q2FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q4FY21
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY23
Presentation Q3FY22
Presentation Q2FY24
Presentation Q1FY21

Company News

Shilpa Medicare informs about disclosure 28 Aug, 5:32 PM Shilpa Medicare informs about letter to shareholders 28 Aug, 5:25 PM Shilpa Medicare’s arm to form new joint venture company in Saudi Arabia 28 Aug, 11:11 AM Shilpa Medicare informs about updates 28 Aug, 9:37 AM Shilpa Medicare - Quaterly Results 13 Aug, 3:31 PM Shilpa Medicare - Quaterly Results 13 Aug, 3:31 PM Shilpa Medicare - Quaterly Results 13 Aug, 3:31 PM Shilpa Medicare receives CDSCO approval for NorUDCA Tablets 9 Aug, 3:17 PM Shilpa Medicare informs about conference call 6 Aug, 2:29 PM Shilpa Medicare receives EIR with VAI for Bengaluru Unit 16 Jul, 12:00 PM Shilpa Medicare informs about updates 16 Jul, 10:53 AM Shilpa Medicare receives GMP certification from SFDA for Unit VI facility 10 Jul, 2:51 PM Shilpa Medicare’s arm completes GMP inspection from Brazilian regulatory authority 7 Jul, 12:51 PM Shilpa Medicare informs about analyst meet 20 Jun, 5:22 PM Shilpa Medicare - Quaterly Results 26 May, 5:49 PM Shilpa Medicare - Quaterly Results 26 May, 5:49 PM Shilpa Medicare - Quaterly Results 26 May, 5:49 PM Shilpa Medicare’s arm enters into strategic partnership with Orion Corporation 23 May, 3:51 PM USFDA issues EIR to unit-1 of Shilpa Medicare’s arm 15 May, 10:08 AM Shilpa Medicare receives GMP approval from European Medicines Agency 6 May, 12:59 PM Shilpa Medicare gets USFDA’s approval for Varenicline Tablets 9 Apr, 5:12 PM Shilpa Medicare informs about compliances-certificate 9 Apr, 4:54 PM Shilpa Medicare’s marketing partner launches BORUZU in US market 3 Apr, 3:40 PM USFDA concludes inspection at Unit-2 of Shilpa Medicare’s arm in Raichur 15 Mar, 3:36 PM Shilpa Medicare informs about disclosure 15 Mar, 11:39 AM Shilpa Medicare informs about inspection 8 Mar, 12:22 PM USFDA concludes inspection at Unit-1 of Shilpa Medicare’s arm in Raichur 8 Mar, 11:48 AM Shilpa Medicare - Quaterly Results 10 Feb, 2:31 PM Shilpa Medicare - Quaterly Results 10 Feb, 2:31 PM Shilpa Medicare - Quaterly Results 10 Feb, 2:31 PM Shilpa Medicare informs about disclosure 23 Jan, 5:32 PM Shilpa Medicare’s arm gets CEP from EDQM for API, Teriflunomide 23 Jan, 3:28 PM Shilpa Medicare gets marketing authorization from Portugal for Tadalafil Orodispersible Films 10 Jan, 2:43 PM Shilpa Medicare gets GMP approval of Eurasia for Unit IV and Unit VII 27 Dec, 12:58 PM Shilpa Medicare informs about transcript of conference call 20 Nov, 12:11 PM Shilpa Medicare informs about updates 19 Nov, 2:38 PM Shilpa Medicare’s arm gets CEP from EDQM for API, Nifedipine 19 Nov, 12:42 PM Shilpa Medicare’s arm gets CEP from EDQM for API Octreotide 18 Nov, 5:38 PM Shilpa Medicare - Quaterly Results 13 Nov, 4:14 PM Shilpa Medicare - Quaterly Results 13 Nov, 4:14 PM Shilpa Medicare informs about updates 31 Oct, 2:54 PM USFDA concludes inspection at Shilpa Medicare’s Bengaluru unit 31 Oct, 12:30 PM Shilpa Medicare informs about closure of trading window 28 Sep, 3:29 PM Shilpa Medicare informs about disclosure 27 Sep, 2:58 PM Shilpa Medicare informs about revised disclosure 27 Sep, 2:46 PM Shilpa Medicare informs about appointment of CEO 19 Sep, 4:45 PM Shilpa Medicare informs about proceedings of AGM 17 Sep, 1:09 PM Shilpa Medicare secures USFDA’s approval for Bortezomib Injection 27 Aug, 2:57 PM Shilpa Medicare informs about disclosure 26 Aug, 10:56 AM Shilpa Medicare completes phase-3 clinical studies of novel product SMLNUD07 - NorUDCA 26 Aug, 10:41 AM

Shilpa Medicare Stock Price Analysis and Quick Research Report. Is Shilpa Medicare an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Shilpa Medicare. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Shilpa Medicare has a PE ratio of 130.007237483873 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Shilpa Medicare has ROA of 1.0912% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Shilpa Medicare has a Current ratio of 1.6653.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Shilpa Medicare has a ROE of 1.2646%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Shilpa Medicare has a Debt to Equity ratio of 0.0665 which means that the company has low proportion of debt in its capital.

  • Sales growth: Shilpa Medicare has reported revenue growth of 25.0642% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Shilpa Medicare for the current financial year is 7.12393628388058%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Shilpa Medicare is Rs 0 and the yield is 0.1208%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Shilpa Medicare is Rs 6.3558. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Shilpa Medicare in Ticker for free. Also, one can get the intrinsic value of Shilpa Medicare by using Valuation Calculators, which are available with a Finology ONE subscription. 

Shilpa Medicare FAQs

Q1. What is Shilpa Medicare share price today?
Ans: The current share price of Shilpa Medicare is Rs 826.3.

Q2. What is the market capitalisation of Shilpa Medicare?
Ans: Shilpa Medicare has a market capitalisation of Rs 8080.46272804 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Shilpa Medicare?
Ans: The PE ratio of Shilpa Medicare is 130.007237483873 and the P/B ratio of Shilpa Medicare is 2.96935203226147, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Shilpa Medicare share?
Ans: The 52-week high share price of Shilpa Medicare is Rs 1000, and the 52-week low share price of Shilpa Medicare is Rs 555.

Q5. Does Shilpa Medicare pay dividends?
Ans: Currently, Shilpa Medicare pays dividends. Dividend yield of Shilpa Medicare is around 0.1208%.

Q6. What are the face value and book value of Shilpa Medicare shares?
Ans: The face value of Shilpa Medicare shares is Rs 1, while the book value per share of Shilpa Medicare is around Rs 278.2762. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Shilpa Medicare?
Ans: Shilpa Medicare has a total debt of Rs 142.5466 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Shilpa Medicare?
Ans: The ROE of Shilpa Medicare is 1.2646% and ROCE of Shilpa Medicare is 2.36%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Shilpa Medicare a good buy for the long term?
Ans: The Shilpa Medicare long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Shilpa Medicare undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Shilpa Medicare appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Shilpa Medicare’s financials?
Ans: You can review Shilpa Medicare’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Shilpa Medicare

Shilpa Medicare Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Shilpa Medicare Ltd. is a renowned pharmaceutical company that has made significant strides in the healthcare industry. With its headquarters located in the city of Raichur, Karnataka, the company has built a strong foundation in manufacturing and marketing a wide range of active pharmaceutical ingredients (APIs) and formulations. Shilpa Medicare Ltd. aims to provide affordable and accessible healthcare solutions to patients globally.

Shilpa Medicare Ltd. – Share Price

The share price of Shilpa Medicare Ltd. is a key indicator for potential investors. It reflects the market's perception of the company's performance and future prospects. Our pre-built screening tools enable investors to track the historical share price movements of Shilpa Medicare Ltd. and analyze the trends over time.

Shilpa Medicare Ltd. – Balance Sheet

The balance sheet of Shilpa Medicare Ltd. provides a snapshot of the company's financial position. It showcases the company's assets, liabilities, and shareholders' equity at a specific point in time. By studying the balance sheet, long-term investors can gain insights into the company's financial stability and growth potential. Our premium features allow investors to conduct fair value calculations using tools such as DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis.

Shilpa Medicare Ltd. – Annual Report

The annual report of Shilpa Medicare Ltd. provides a comprehensive overview of the company's performance and achievements during a particular fiscal year. It includes detailed information about the company's business operations, financial statements, management discussions, and future strategies. Investors can download the annual reports from our website to gain deeper insights into Shilpa Medicare Ltd.'s activities.

Shilpa Medicare Ltd. – Dividend

Shilpa Medicare Ltd. acknowledges the value of its shareholders and has consistently rewarded them through dividends. Dividends are a portion of the company's profits distributed to shareholders as a return on their investments. The company's dividend policy, trends, and payout ratios can offer valuable information to long-term investors evaluating the attractiveness of Shilpa Medicare Ltd. as an investment opportunity.

Shilpa Medicare Ltd. – Quarterly Result

The quarterly results of Shilpa Medicare Ltd. provide a closer look at the company's financial performance and progress on a short-term basis. By analyzing the quarterly results, investors can assess the company's ability to generate revenue, manage costs, and sustain growth. Our website offers downloadable quarterly reports, allowing investors to stay updated on Shilpa Medicare Ltd.'s latest financial developments.

Shilpa Medicare Ltd. – Stock Price

Monitoring the stock price of Shilpa Medicare Ltd. is crucial for investors seeking stock analysis. Our pre-built screening tools provide access to real-time stock price data, historical price charts, and customizable technical indicators. With these tools, investors can track the movements of Shilpa Medicare Ltd.'s stock price and make informed decisions based on market trends and patterns.

Shilpa Medicare Ltd. – Price Chart

The price chart of Shilpa Medicare Ltd. enables investors to visually analyze the historical performance of the company's stock. By studying the price chart, long-term investors can identify trends, patterns, and potential buying or selling opportunities. Our website's pre-built screening tools incorporate advanced charting features to assist investors in conducting technical analysis effectively.

Shilpa Medicare Ltd. – News

Staying updated with the latest news about Shilpa Medicare Ltd. is essential for investors seeking stock analysis. Our website provides curated news articles that cover the company's recent developments, regulatory updates, partnerships, and product launches. Investors can access these news articles to gain insights into the factors that may influence Shilpa Medicare Ltd.'s stock performance.

Shilpa Medicare Ltd. – Concall Transcripts

Concall transcripts offer investors valuable information by providing a detailed record of the company's conference calls or earnings calls. These transcripts contain discussions between company management and analysts, providing insights into the company's financial results, future plans, and market outlook. Investors can download the concall transcripts from our website to gain a deeper understanding of Shilpa Medicare Ltd.'s operations and strategies.

Shilpa Medicare Ltd. – Investor Presentations

Investor presentations play a significant role in understanding a company's performance, strategies, and future growth prospects. Shilpa Medicare Ltd. provides downloadable investor presentations on our website to keep investors informed about the company's recent initiatives, financial highlights, and expansion plans. These presentations offer valuable insights to long-term investors looking for stock analysis.

Shilpa Medicare Ltd. – Promoters

Shilpa Medicare Ltd. is backed by a group of dedicated promoters who have been instrumental in shaping the company's growth and success. The promoters bring their expertise, vision, and strategic guidance to drive the company forward. Understanding the profile and background of the promoters can provide investors with valuable insights into the company's stability and growth potential.

Shilpa Medicare Ltd. – Shareholders

Shilpa Medicare Ltd. benefits from a diverse base of shareholders who have placed their trust in the company's potential for long-term growth. Monitoring the shareholder composition can provide investors with insights into the market sentiment towards Shilpa Medicare Ltd. and the level of conviction among institutional investors. Our pre-built screening tools enable investors to track changes in shareholder patterns and identify significant stakeholders.

At our website, we provide a range of tools and resources for long-term stock investors seeking comprehensive stock analysis of Shilpa Medicare Ltd. Our pre-built screening tools, downloadable annual reports, concall transcripts, investor presentations, and premium features for fair value calculations offer investors a wealth of information to make informed investment decisions.

Read More
X